Claims
- 1. A recombinant antibody or antigen-binding fragment thereof which binds to a mammalian CC-chemokine receptor 2 protein, wherein said recombinant antibody or antigen-binding fragment thereof inhibits binding of a chemokine to said receptor protein and inhibits one or more functions associated with binding of the chemokine to said receptor protein, and wherein said recombinant antibody or antigen-binding fragment thereof binds the amino-terminal domain of said receptor protein.
- 2. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein said mammalian receptor protein is a human receptor protein.
- 3. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein said recombinant antibody or antigen-binding fragment thereof can compete with monoclonal antibody 1D9 for binding to said receptor protein.
- 4. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 1D9.
- 5. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 1D9.
- 6. A recombinant antibody or antigen binding fragment thereof according to claim 5, wherein said chineric antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 1D9.
- 7. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein said recombinant antibody or antigen-binding fragment thereof can compete with monoclonal antibody 8G2 for binding to said receptor protein.
- 8. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more antigen-binding regions of monoclonal antibody 8G2.
- 9. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein said recombinant antibody or antigen-binding fragment thereof comprises one or more complementarity-determining regions of monoclonal antibody 8G2.
- 10. A recombinant antibody or antigen-binding fragment thereof according to claim 9, wherein said recombinant antibody or antigen-binding fragment thereof comprises six complementarity-determining regions of monoclonal antibody 8G2.
- 11. A composition comprising a recombinant antibody or antigen-binding fragment thereof according to claim 1 and an optional physiologically acceptable vehicle.
- 12. A pharmaceutical composition comprising a recombinant antibody or antigen-binding fragment thereof according to claim 1 and a physiologically acceptable vehicle.
- 13. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein said recombinant antibody or antigen-binding fragment thereof is a chimeric antibody or antigen-binding fragment thereof.
- 14. A recombinant antibody or antigen-binding fragment thereof according to claim 1, wherein said recombinant antibody or antigen-binding fragment thereof is a humanized antibody or antigen-binding fragment thereof.
RELATED APPLICATION
[0001] This application is a divisional of U.S. patent application Ser. No. 09/121,781, filed Jul. 23, 1998, the entire teachings of which are incorporated herein by reference.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09121781 |
Jul 1998 |
US |
Child |
09866970 |
May 2001 |
US |